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Introduction
In addition to the established role as inhibitors of osteo-
clast activity and bone resorption, bisphosphonates (BPs) 
also aﬀ  ect tumour cells. Th   eir ability to induce apoptosis, 
reduce proliferation, and inhibit tumour cell migration 
and invasion has been demonstrated in numerous in vitro 
studies (reviewed in [1]). As nitrogen-containing BPs 
(NBPs) act by inhibiting key enzymes in the metabolic 
pathway responsible for cholesterol synthesis, which is 
essential for all nucleated cells, the drugs do have the 
potential to aﬀ  ect any cell type that takes up suﬃ   cient 
quantities of them [2].
Th   e anti-tumour eﬀ  ects reported from in vitro systems 
led to subsequent investigations using in vivo models in 
diﬀ  erent tumour types, including breast cancer (reviewed 
in [3]). Most of these focussed on elucidating the eﬀ  ects 
of BPs on tumours in bone, and it quickly became clear 
that BP treatment prevented the development of cancer-
induced bone disease, but that tumour growth was only 
temporarily halted and eventually progressed. Increasing 
the dosing frequency and/or starting therapy at early 
stages of the disease process increased the anti-tumour 
eﬀ  ect, but did not completely eradicate tumours.
Subsequent studies explored the potential of BPs as 
part of combination therapy schedules. BPs were added 
to a range of standard chemotherapy agents used to treat 
breast, prostate and small cell lung cancer, multiple 
myeloma and osteosarcoma [3,4]. In all reports published 
to date, addition of a BP to other anti-cancer therapies 
caused signiﬁ  cantly decreased tumour burden compared 
to that seen when the single agents were used. Th   is has in 
turn led to clinical trials in breast cancer investigating 
whether adding BPs to standard treatment translates to 
additional beneﬁ  t for patients [5,6]. Although substantial 
increased anti-tumour eﬀ   ects are demonstrated when 
BPs are added to a range of therapeutic agents, the 
underlying molecular and cellular mechanisms remain to 
be established.
Over the past decade it has become apparent that the 
tumour microenvironment has a key role in both cancer 
development and determining the response to therapy. A 
multitude of cellular and molecular interactions take 
place between malignant and normal cells during tumour 
progression, and increasingly the normal cells are 
considered to be therapeutic targets in their own right. 
Th  ese interactions take place at several diﬀ  erent levels; 
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and molecules that comprise their local, medial and distal 
microenvironment (Figure 1). BPs are prime examples of 
agents that modify the normal cells of the bone 
microenvironment and thereby have profound eﬀ  ects on 
tumour progression. Th  e potential for these agents to 
also aﬀ  ect cells distal to bone is currently an area of active 
research.
Anti-tumour eff  ects of bisphosphonates - direct, 
indirect or both?
Th  e high aﬃ     nity BPs have for bone is key to their 
successful use in the treatment of a number of skeletal 
disorders [7]. BPs rapidly home to bone following 
adminis  tration, with a half-life in serum of only a few 
hours [8-10]. BPs can, however, be retained in the skele-
ton for several years, and during normal bone turn  over 
small amounts of BPs may be released into the circu  lation 
and thereby potentially aﬀ  ect peripheral tissues.
Th  ere is broad agreement that due to the high 
concentration of BPs in bone, bone metastases are the 
tumours most likely to be directly exposed to signiﬁ  cant 
levels of the drugs for prolonged periods of time, and 
tumour cells residing in bone may be directly aﬀ  ected 
through uptake of BPs released during normal bone 
turnover. Th  e current evidence for this proposed direct 
anti-tumour eﬀ  ect is not compelling, as we are unable to 
measure the local ‘free’ concentration of BPs in metastatic 
foci. In addition, the presence of BPs eﬀ  ectively reduces 
bone resorption, thereby limiting the amount of drug 
released to subsequently aﬀ  ect resident tumour cells.
A recent report indicates that there may be alternative 
explanations for the anti-tumour eﬀ   ects of BPs, not 
involving osteoclasts. Th  is study investigated the eﬀ  ects 
of zoledronic acid on B16 melanoma bone tumour 
burden in irradiated mice that had received a transplant 
of splenic cells from src-/- mice that lack functional 
osteo  clasts [11]. Th  is elegant approach allowed the 
researchers to study the eﬀ   ects of zoledronic acid on 
tumour growth in bone, independent of any eﬀ  ects on 
bone resorption. Intriguingly, zoledronic acid caused an 
88% reduction in bone tumour growth compared to 
irradiated vehicle-treated controls, strongly indicative of 
osteoclast-independent eﬀ   ects on tumour cells. Th  e 
authors suggest that eﬀ   ects on endothelial cells or 
perhaps direct eﬀ  ects on the tumour cells may cause the 
reduced tumour growth, but the cellular and molecular 
mechanisms remain unknown.
Within bone it is likely that a combination of direct and 
indirect eﬀ  ects of BPs contribute to inhibiting tumour 
growth and the associated cancer-induced bone disease 
[12]. In contrast, we know little about how inhibiting 
bone resorption aﬀ   ects tumours outside the skeleton. 
Perhaps BPs disrupt the migration of bone marrow 
precursors that are essential for peripheral tumour 
growth, thereby indirectly reducing tumour burden. Th  is 
is an area of great interest, as a recent clinical study has 
indicated that even 6-monthly administration of the 
potent BP zoledronic acid improves outcome for breast 
cancer patients by reducing local recurrence [13]. 
Zoledronic acid is reported to reduce granulocyte-
macrophage colony stimulating factor (GM-CSF)-
stimulated tumour growth in bone, and this may partly 
be due to inhibition of mobilisation of dormant tumour 
cells during active bone resorption [14].
BPs may also aﬀ  ect disseminated tumour cells in the 
bone marrow, as demonstrated in a study of women with 
locally advanced breast cancer [15]. In this study, 
zoledronic acid added to neo-adjuvant chemotherapy 
reduced the number of patients with detectable 
disseminated tumour cells in the bone marrow at 3 
months compared to those that received chemotherapy 
alone. Evidence for a direct eﬀ  ect of zoledronic acid on 
primary breast tumours has been reported in a separate 
neo-adjuvant study that was incorporated in the AZURE 
trial [16]. Patients receiving zoledronic acid in addition to 
standard therapy had signiﬁ   cantly smaller residual 
invasive tumour size compared to those receiving 
standard therapy alone. Th   ere are thus emerging clinical 
data to support a wider therapeutic eﬀ  ect of BPs in breast 
cancer. In breast cancer models, BPs aﬀ  ect a range of cell 
types contributing to tumour development, including 
those of the local and distal tumour microenvironment 
(Figures 2 and 3). Th   e following sections will give some 
examples of studies investigating the eﬀ  ects of BPs on 
diﬀ  erent cell types in vitro and in vivo.
Bisphosphonates may modify a range of cell types
From  in vitro studies we know that BPs may induce 
apoptosis and reduce proliferation of a range of tumour 
cells, but high and/or frequent dosing has often been 
used to generate these eﬀ  ects [1]. In addition, eﬀ  ects on 
other cell types, including endothelial cells [17], macro-
phages [18], immune cells [19], osteoblasts [20], ﬁ  bro-
blasts and stromal cells [21], have been reported in vitro. 
Subsequent studies using in vivo tumour models showed 
that reduced tumour growth is associated with changes 
in the tumour microenvironment - for example, reduced 
vascularisation and macrophage inﬁ   ltration [22]. As 
shown in Figure 2, BPs may modify a number of 
processes and cell types involved in the development and 
progression of peripheral tumours. In all cases, the 
question of dose and distribution of BPs following a 
clinical administration is key. Cells of peripheral tumours 
are exposed to very low levels of BPs for a short period of 
time, whereas tumour cells in bone are likely to encounter 
higher concentrations of BPs. Th  e lack of suitable 
research tools has hampered studies of the distribution 
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precise molecular and cellular BP targets within tumours, 
and the eﬀ  ects of changes in systemic factors remain to 
be ﬁ  rmly established (Table 1).
Anti-angiogenic eff  ects of BPs potentially 
contribute to reduced tumour growth
Key to tumour development is the ability to establish a 
functional blood supply to support the high metabolic 
activity of a rapidly growing tumour mass; thus, the 
tumour vasculature represents an attractive but elusive 
therapeutic target. Th  e potential for BPs to modify 
tumour angiogenesis has been addressed in several 
studies, summarised in the following sections.
Eff  ects on cells of the normal vasculature
BPs may elicit their proposed anti-angiogenic eﬀ  ects 
through inhibiting maturation and/or proliferation of 
endothelial cells (ECs), by aﬀ  ecting their adhesion, or by 
reducing their ability to migrate and form functional 
vessels. Several of these processes are driven by vascular 
endothelial growth factor (VEGF), and hence may be 
modiﬁ  ed through a BP-mediated reduction in the level of 
this key pro-angiogenic factor [23]. Interest in this area 
has been rekindled by the reports of cases of osteo-
necrosis of the jaw (ONJ) following treatment with zole-
dronic acid [24]. Reduced vascularisation is suggested to 
be one of the contributing factors of ONJ, potentially 
mediated via the reported anti-angiogenic eﬀ  ects  of 
zoledronic acid. However, recent reports of ONJ follow-
ing treatment with the new anti-resorptive agent denosu-
mab would indicate that eﬀ  ects on osteoclasts are central 
to ONJ [25].
Th  e anti-angiogenic eﬀ  ects of BPs were ﬁ  rst investi-
gated using primary endothelial cells [17]. Human 
umbilical cord-derived ECs (HUVECs) were treated with 
increasing doses of zoledronic acid or pamidronate in 
vitro, and the eﬀ  ect on EC apoptosis, proliferation and 
migration and vessel sprouting were determined. Th  is 
study clearly demonstrated how cellular processes have 
Figure 1. The main components of the tumour microenvironment.
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growth factor-stimulated HUVEC proliferation was 
signiﬁ  cantly reduced by a low dose of zoledronic acid 
(3 μM for 24 hours), a reduction in cell adhesion required 
exposure to 30 μM for 48 hours, and exposure to 100 μM 
for 48 hours was needed to induce a signiﬁ  cant increase 
in the levels of HUVEC apoptosis. Both BPs were found 
to reduce angiogenesis in the vessel sprouting assays, but 
doses as high as 1 mM were applied, thus limiting the 
clinical relevance of these ﬁ  ndings. In an in vivo angio-
genesis assay, zoledronic acid caused 98.5% and 46% 
reduc  tions in blood volume of basic ﬁ  broblast growth 
factor and VEGF implants, respectively, compared to 
control.
In general, endothelial cells are less sensitive to BPs 
compared to tumour cells. Th   is is probably due to the low 
endocytic uptake of BPs in these cells, coupled with their 
long cycling time in vitro. Human dermal microvascular 
endothelial cells (HuDMECs) have been shown to take up 
BPs, as demonstrated by accumulation of unprenylated 
Rap1a (a surrogate marker for NBP uptake) [26]. Th  e  cells 
of the normal vasculature appear to be less sensitive to 
BPs than tumour cells and highly endocytic/phagocytic 
cells (like osteoclasts and macrophages) [26].
Eff  ects on endothelial progenitor cells
Th  e majority of studies to date have focussed on endo-
thelial cell function, but two recent reports suggest that 
BPs may perhaps also reduce the viability and maturation 
of EC precursors. Zeibart and colleagues [27] demon-
strated that 48-hour in vitro exposure to zoledronic acid, 
ibandronate, clodronate or pamidronate reduced the 
viability of human endothelial progenitor cells (EPCs) 
isolated from peripheral blood mononuclear cells. Zole-
dronic acid was the most potent compound, reducing EPC 
numbers by more than 40% following 48-hour incubation 
with 50 μM. Th  ese results suggest that the high concen-
tration of BPs in bone may reduce the viability of resident 
EPCs, causing a downstream inhibition of angiogenesis.
An independent investigation by Yamada and 
colleagues [28] addressed whether zoledronic acid can 
inhibit EPC diﬀ  erentiation from peripheral blood mono-
nuclear cells. Th  e phenotype of the cells was charac-
terised by measuring their expression of VE-cadherin/
CD144 and VEGF receptor 2 (VEGFR2), and the 
functionality assessed through the ability of the cells to 
form tubules on matrigel. Exposure of the EPCs to the 
relatively low doses of 1 and 5 μM zoledronic acid for 
5  days caused the cells to retain a rounded EPC 
Figure 2. Potential anti-tumour eff  ects of bisphosphonates (BPs) outside the skeleton.
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thelial cell markers, as well as a reduced capacity to form 
tubules in a matrigel assay. Th  ese  eﬀ  ects were reversed by 
inclusion of geranylgerinaol, and thus possibly mediated 
through disrupting the cellular localisation of small 
GTPases [29].
Eff  ects on tumour angiogenesis
BPs may also reduce tumour vascularisation. However, 
there have been few studies addressing this in detail due 
to technical diﬃ     culties in establishing reliable model 
systems. Recent developments in advanced imaging 
systems mean the biological eﬀ  ects may now be more 
readily addressed [30,31].
Reports that zoledronic acid causes decreased plasma 
VEGF levels in advanced cancer patients [23] led to a 
number of studies of the potential link between anti-
tumour and anti-angiogenic eﬀ   ects of BPs [22,32-35]. 
However, in most of these studies the suggested eﬀ  ects of 
BPs on tumour angiogenesis are based on observations of 
apparently reduced levels of micro-vessel density, asso-
ciated with a decrease in tumour volume. No attempts 
Figure 3. Potential anti-tumour eff  ects of bisphosphonates (BPs) in bone.
Table 1. Overview of processes determining the anti-tumour eff  ects of bisphosphonates outside bone 
Factors contributing to anti-tumour
eff  ects of BPs in peripheral tumours  Questions still to be resolved
Concentration in tumour  What concentration of BPs reaches the tumour following a clinical dose?
Cellular uptake  How much BP is taken up by the tumour cells and by the cells of the local tumour microenvironment?
Duration and clearance  How long is BP retained in the cells and within the tumour mass?
Molecular and cellular targets  What are the specifi  c molecular targets of BPs in tumour cells and in the cells of the tumour microenvironment?
Systemic eff  ects  BPs may reduce the levels of circulating factors like VEGF, thereby aff  ecting tumour growth indirectly 
Eff  ects on bone marrow precursors  BPs may inhibit recruitment of bone marrow precursors essential for primary tumour growth 
Activation of γδ T cells  BPs may facilitate tumour killing through activation of anti-tumourigenic γδ T cells 
Release of BPs from bone  Does long-term release of low levels of BPs during normal bone turnover reach levels that aff  ect peripheral tumours?
BP, bisphosphonate; VEGF, vascular endothelial growth factor.
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administration of BPs and reduced tumour micro-vessel 
density. Whether the decrease in tumour vascularisation 
directly reduces tumour growth, or vice versa, therefore 
remains to be established. Changes in the tumour 
vasculature may precede eﬀ   ects on bone lesions, as 
indicated by a recent study utilising dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI) to 
investigate the eﬀ  ects of zoledronic acid and sunitinib 
malate in experimental breast cancer bone metastases in 
nude rats [30].
Eff  ects on tumour macrophage infi  ltration
A high level of macrophage inﬁ  ltration is associated with 
poor prognosis in several tumour types [36], and ablation 
of macrophages in breast cancer models has been shown 
to reduce tumour growth and progression [37]. Tumour 
cells release a range of chemotactic factors that attract 
circulating monocytes, which subsequently mature to 
become tumour macrophages. In breast cancer models, 
macrophages have been shown to regulate the angiogenic 
switch required for tumour vascularisation [38]. Hence, 
there is considerable evidence that tumour-associated 
macrophages contribute to driving breast cancer develop-
ment, and therefore represent a therapeutic target.
Although the main cellular targets of BPs are the bone-
resorbing osteoclasts, early work to identify the 
molecular mechanism of action of BPs was performed 
using the JJN4 mouse macrophage cell line [39]. BPs 
induced macrophage apoptosis in vitro, and peritoneal 
macrophages have subsequently been shown to take up 
zoledronic acid following in vivo administration [40]. 
Whether tumour macrophages also take up BPs in vivo is 
currently unknown, but a recent study demonstrated 
signiﬁ   cantly reduced tumour macrophage inﬁ  ltration 
caused by zoledronic acid in a model of spontaneous 
mammary carcinoma [22]. Zoledronic acid-treated 
animals displayed fewer and smaller mammary tumours 
compared to the untreated control animals, and 
increased survival. Th   e reduced tumour burden following 
zoledronic acid treatment was associated with decreased 
levels of circulating VEGF, and reduced tumour vascu-
lari  sation and number of tumour-associated macro-
phages. In addition, there was a repolarisation of the 
macro  phages from a M2 to a tumouricidal M1 phenotype 
in zoledronic acid-treated animals. Th  ese data suggest 
that the anti-tumour eﬀ   ects of zoledronic acid are 
mediated through depletion of macrophages required for 
vasculari  sation of the tumour, rather than through 
aﬀ  ecting tumour cells directly. One key limitation to the 
direct transfer of these promising data to human cancer 
is that zoledronic acid treatment had to be started early 
in tumour development (at the hyperplastic stage) in 
order to inhibit tumour growth.
Similar data have been reported in a previous study 
using the same model to investigate the eﬀ  ects of BPs on 
bone marrow hematopoiesis [18]. Th  e  mammary 
tumours in BALB-neuT mice produce VEGF, which in 
turn stimulates production of myeloid-derived suppres-
sor cells. Daily administration of pamidronate (2 mg/kg) 
or zoledronic acid (100 μg/kg) starting at 4 or 7 weeks 
(hyperplastic stage) caused signiﬁ  cantly reduced tumour 
growth compared to control, whereas this was less pro-
nounced if treatment started at 12 weeks when numerous 
mammary carcinomas were established. Zoledronic acid 
caused a reduction in the levels of circulating pro-matrix 
metalloproteinase-9 and VEGF, accompanied by 
decreased inﬁ   ltration of macrophages in the tumour 
stroma, and reduced myeloid-derived suppressor cell 
expansion in both bone marrow and peripheral blood.
Th   e suggestion that early BP treatment may be required 
to reduce tumour growth is supported by data from a 
study using established breast cancer xenografts, where 
animals with palpable, subcutaneous MDA-MB-436 
derived tumours were administered up to 6 mg/kg of 
zoledronic acid once weekly for 6 weeks [41]. In contrast 
to the data described above, zoledronic acid did not 
reduce tumour growth, even at the highest concen-
trations used (60× equivalent of the 4-mg clinical dose). 
Th  ese data highlight the need for caution when inter-
preting and comparing results reported from in vivo 
studies, as diﬀ  erent models representing diﬀ  erent stages 
of tumour development may display variability in terms 
of sensitivity to anti-cancer agents [42]. In particular, 
there may be signiﬁ  cant  diﬀ  erences  in  therapeutic 
response recorded between xenograft studies that use 
immunocompromised mice and studies using murine 
mammary carcinoma models in immunocompetent mice.
Immunomodulatory eff  ects of BPs may contribute 
to their anti-tumour eff  ects
Although BPs are generally very well tolerated, around a 
third of patients receiving intravenous NBPs, such as 
zoledronic acid, experience a short-term acute phase 
response, mainly after the initial infusion. Th  e mecha-
nism triggering this response was ﬁ  rst  identiﬁ  ed  in 
patients with multiple myeloma receiving intravenous 
pamidronate, where it was found that the acute phase 
response was linked to increased levels of circulating γδ 
T cells [43]. Subsequent studies revealed that BPs acti-
vated a particular subset of γδ T cells (Vγ9Vδ2), leading 
to increased release of pro-inﬂ  ammatory cytokines and 
hence initiating acute phase response. Th  e mechanism 
behind activation of γδ T cells has been shown to be the 
accumulation of isopentenyl diphosphate and dimethyl-
allyl pyrophosphate, following inhibition of farnesyl 
diphosphate synthase by NBPs [19]. In humans, γδ T 
cells constitute a minor proportion of T cells that are 
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has been hypothesised that activation of γδ T cells by 
NBPs may result in triggering of an anti-tumour immune 
response leading to tumour cell death. Small-scale 
clinical feasibility studies have been performed to explore 
the potential of using NBPs as immuontherapy to trigger 
an anti-tumour response [44]. However, the clinical 
signiﬁ     cance of γδ T cell activation in the context of 
potential anti-tumour eﬀ  ects remains to be established.
In addition to the diﬀ  erent processes aﬀ  ected by BPs 
described above, their anti-tumour eﬀ   ect may also 
involve other elements of the tumour microenvironment - 
for example, inhibition of proteolytic enzymes required 
for tumour cell migration, and modiﬁ   cation of the 
capacity of bone marrow precursor cells to migrate to 
peripheral tissues (Figures 2 and 3).
Anti-tumour eff  ects of BPs in models of breast 
cancer bone metastases
Th  e  eﬀ  ects of BPs on lytic bone disease have been investi-
gated in great detail, conﬁ   rming that BPs inhibit the 
development of bone lesions and thereby increase 
survival [3]. Reduced lesion volume is generally asso-
ciated with a decrease in skeletal tumour burden, 
suggest  ing that BPs have anti-tumour eﬀ  ects in bone. But 
do BPs reduce tumour growth directly, or is their positive 
eﬀ   ect mediated exclusively through the protection of 
bone from further destruction stimulated by tumour 
cells? Th  e studies discussed in the following section 
(Table 2) illustrate that it has been diﬃ   cult to dissect the 
direct from the indirect anti-tumour eﬀ  ects of BPs in 
bone metastasis models.
Bisphosphonates used as single agents
Data from in vitro and in vivo studies have demonstrated 
that BPs have the capacity to modify a number of cell 
types and processes involved in the development and 
progression of bone metastases [3] (Figure 3). Early 
studies focussed on the ability of BPs to prevent or reduce 
the extent of breast cancer-induced bone disease were 
performed by Sasaki and colleagues [45] using 
MDA-MB-231 human breast cancer cells implanted by 
intracardiac injection into female BALB/c-nu/nu mice to 
generate tumour foci in bone. Animals received 
risedronate either in the setting of established bone 
metastases, in an early treatment protocol from the day 
of tumour cell inoculation, or in a prevention protocol. In 
all cases, risedronate treatment reduced the development 
or slowed progression of bone lesions, and this was 
associated with increased numbers of apoptotic osteo-
clasts at the metastatic sites. Th  e authors noted that 
risedronate caused a surprising reduction in the intra-
osseous tumour burden, whereas tumour growth in 
bone-associated soft tissues was unaﬀ  ected. Th  is  was  the 
ﬁ   rst indication that BPs may have bone-speciﬁ  c  anti-
tumour eﬀ  ects.
Sasaki and colleagues went on to repeat their study to 
investigate the eﬀ   ect of minodronic acid (a third 
generation BP) using the same model and treatment 
protocols [46]. Daily administration of minodronic acid 
Table 2. Overview of studies investigating bisphosphonates in models of breast cancer bone metastases
Breast cancer model  Bisphosphonate (dose)  Eff  ect  Reference
MDA-MB-231: intracardiac   Risedronate (0.4, 4 and  Reduced osteolytic lesion volume  [45]
implantation  40 μg/mouse/day)  Reduced intra-osseous tumour volume
    Increased bone-associated soft tissue tumour burden
MDA-MB-231: intracardiac   YH529 (0.2, 2 and  Reduced osteolytic lesion volume  [46]
implantation  20 μg/mouse/day)  Reduced intra-osseous tumour volume
    Increased bone-associated soft tissue tumour burden after 
    0.2 and 2 μg doses, decreased after 20 μg
4T1/luc: bone metastases  Zoledronic acid (0.5 and  Reduced osteolytic lesion volume  [51]
  5 μg/mouse)  Increased tumour cell apoptosis
MDA-MB-231: intracardiac   Ibandronate (4 μg/mouse/day,  Reduced osteolytic lesion volume  [49]
implantation  7 days)  Reduced intra-osseous tumour volume
MDA-MB-231: injected in   Ibandronate (10 μg/kg/day)  Reduced osteolytic lesion volume  [50]
femoral artery, nude rats    Reduced intra-osseous tumour volume
MDA-MB-231/luc: intracardiac   Olpandronate (1.6 μm/kg/day,  Olpandronate: reduced osteolytic lesion volume and reduced  [47]
and intra-osseous implantation  18 days/40 days)  intra-osseous tumour volume
  Pamidronate (1.6 μm/kg/day,  Pamidronate: reduced lytic lesions and intra-osseous tumour growth
  40 days)  after intratibial implantation
   No  eff  ect of BPs on bone-associated soft tissue burden
B02: generates bone metastases   Zoledronic acid (3 and7 μg/kg/day;   Clinically relevant doses used  [52]
following intravenous injection  20 and 50 μg/kg/week;   No eff  ect of a single dose of zoledronic acid 
  100 μg/kg 1×)   Weekly and daily administration of zoledronic acid reduced osteolysis
  Clodronate (530 μg/kg/day)  and intra-osseous tumour growth
    Daily clodronate less eff  ective compared to zoledronic acid
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dependent reduction in osteoclast number, as well as in 
the number and area of osteolytic lesions, and decreased 
bone tumour burden. Short-term treatment (days 17 to 
28) and preventive treatment (7 days before tumour cell 
inoculation) caused similar eﬀ   ects. Only prophylactic 
administration caused near complete inhibition of the 
development of new metastases, indicating that once 
metastases are established they become less sensitive to 
drugs targeting osteoclastic bone resorption. One 
interesting ﬁ   nding was that administration of 0.2 and 
2 μg minodronic acid caused an increase in bone-asso-
ciated soft tissue tumour volume, similar to their earlier 
ﬁ   nding using risedronate [45]. Th  is indicates that BP-
mediated inhibition of bone resorption may cause 
expansion of extra-osseous tumour growth, a common 
ﬁ  nding in studies of late stage disease [47,48]. Th  e  rele-
vance of this observation for human cancer is currently 
unknown.
Whether soft tissue tumours are less sensitive to BP 
therapy compared to tumours in bone was further 
investigated by Hiraga and colleagues [49]. In this study, 
MDA-MB-231 cells were implanted by intracardiac injec-
tion in female BALB/c-nu/nu mice (to generate bone 
metastases), or in the mammary fat pad (to mimic extra-
skeletal tumour growth). Animals were subsequently 
treated with ibandronate (4 μg/mouse/day) once bone 
metastases were established (days 21 to 28), and the same 
treatment was given to animals with tumours implanted 
in the mammary fat pad. Ibandronate had profound 
eﬀ  ects on tumour growth in bone, reducing progression 
of osteolytic lesions, inducing osteoclast apoptosis, 
inhibiting formation of new bone metastases, increasing 
cancer cell apoptosis and reducing tumour burden. In 
sharp contrast, tumour growth in the mammary fat pad 
was unaﬀ  ected, supporting the hypothesis that the anti-
tumour eﬀ  ects of ibandronate are restricted to tumours 
growing within the bone microenvironment. A later 
study, using MDA-MB-231 human breast tumour cells 
injected directly into the femoral artery of male athymic 
rats, also showed that ibandronate (10 μg/kg/day, days 18 
to 30) reduced the extent of the osteolytic lesions [50]. 
Th  is study also provided evidence that once tumours 
have reached a certain size (>6 mm in this model) they 
become less dependent on the bone microenvironment 
for their further expansion, and hence less sensitive to BP 
therapy.
Th  e ﬁ   rst bone metastasis study of the eﬀ  ects  of 
zoledronic acid, the most potent of the BPs, used the 4T1 
mouse mammary tumour model [51]. In this model there 
is spontaneous metastatic spread to bone, lung and liver 
following implantation of 4T1/luc breast cancer cells in 
the mammary fat pad of female BALB/c mice. Th  is  study 
clearly demonstrated that zoledronic acid aﬀ  ects both 
tumour cells and osteoclasts, but did not distinguish 
between direct eﬀ   ects on tumour cells and indirect 
eﬀ  ects via reduced bone resorption.
A study by van der Pluijm and colleagues showed that 
BPs modify tumour growth primarily through eﬀ  ects on 
bone, rather than through targeting tumour cells directly 
[47]. MDA-231-B/luc+ breast cancer cells were im-
planted by intracardiac injection, and olpadronate given 
as a preventive (subcutaneous 1.6  μmol/kg/day from 
2 days before implantation) or a treatment (days 3 to 43) 
schedule. Eﬀ   ects on the forma  tion of new bone 
metastases and osteolysis were assessed, as well as 
tumour burden both inside and outside the bone marrow 
cavity. As expected, BP treatment reduced the level of 
cancer-induced bone disease regardless of schedule, with 
preventive treatment causing a substantial reduction in 
the number of bone metastases. However, the reduction 
in tumour growth was only transient and did not aﬀ  ect 
progression of established tumours. Th  e study also 
included an intra-osseous model, where daily injections 
of pamidronate or olpadronate (1.6 μmol/kg/day) were 
given from day 3 to day 43. In this experiment, both BPs 
caused a signiﬁ   cant reduction of the intra-osseous 
tumour burden. However, there was an increase of the 
total tumour burden (including in the bone-associated 
soft tissues), indicating that tumour growth is shifted 
from the bone marrow cavity to extra-osseous sites.
Th  e optimal dosing regimen of BPs for inhibition of 
tumour growth remains to be established, and whether 
clinically relevant BP doses are suﬃ   cient to aﬀ  ect tumour 
growth is a hotly debated issue. One study has aimed to 
establish whether low, frequent (daily) dosing with BPs is 
superior to weekly administration, and how this com-
pares to a single administration of the same total dose 
[52]. Female BALB/c athymic mice were injected with 
human B02/GFP.2 breast cancer cells (a bone-homing 
subclone of MDA-MB-231) and zoledronic acid 
administered daily (intravenous 3 μg/kg preventive and 
7  μg/kg therapeutic), weekly (20 μg/kg preventive and 
50  μg/kg therapeutic) or as a single dose schedule 
(100  μg/kg preventive or therapeutic). Th  e total accu-
mulated concentration of zoledronic acid was 98 to 
100 μg/kg/mouse, equivalent to the 4-mg clinical dose. 
Clodronate was administered daily at 530 μg/kg, equiva-
lent to the clinical dose of 1,600 mg/day. Both preventive 
and therapeutic administration of clodronate (daily) and 
zoledronic acid (daily or weekly) caused a signiﬁ  cantly 
reduced bone tumour burden, and there was no evidence 
of increased bone-associated soft tissue tumour growth. 
In contrast, the single administration of zoledronic acid 
had only minimal eﬀ  ect on tumour growth, even when 
administered prior to tumour cell inoculation (13% 
reduc  tion compared to control). Importantly, the diﬀ  er-
ent BPs and schedules all inhibited bone resorption to a 
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growth varied. Th  ese intriguing data demonstrate that 
there is a substantial diﬀ  erence in the outcome depending 
on the BP schedule used, and that frequent low dose 
administration has more profound eﬀ   ects on tumour 
growth in bone compared to giving the same total dose as 
a single injection.
Bisphosphonates as part of combination therapy
As the above studies demonstrate at best a limited, 
transient anti-tumour eﬀ   ect of BPs, these agents may 
hold greater promise when used in combination with 
therapies that target tumour cells directly. Th   is has been 
explored in a number of in vitro and in vivo studies, using 
a variety of cancer cell types [1,3].
Initial studies of the eﬀ   ects of the chemotherapy 
regimen UFT (tegafur plus uracil) combined with zole-
dronic acid used the syngeneic 4T1 model, where female 
BALB/c mice were injected orthotopically (mammary fat 
pad) with the murine breast cancer cell line 4T1, resulting 
in dissemination of the tumour cells to bone [53]. A 
single injection of zoledronic acid (250 μg/kg, day 7), or 
oral administration of UFT (20 mg/kg/day, days 14 to 21), 
signiﬁ   cantly reduced the area of bone metastases. 
Combining both therapies caused an increased reduction 
in bone lesions compared to that caused by giving the 
single agents, but crucially there was no reduction in 
tumour volume at the primary site.
Th   e majority of combination therapy studies in breast 
cancer have used xenograft models, where human breast 
cancer cells are implanted in immunocompromised mice 
via intra-cardiac or intra-tibial injection. Most studies 
have been done with zoledronic acid, due to its 
widespread use in the treatment of breast cancer-induced 
bone disease (Table 3). Th  e eﬀ  ects of combining zole-
dronic acid with the antibiotic doxycycline have been 
tested on tumour growth in bone following intracardiac 
injection of MDA-MB-231 human breast cancer cells in 
Balb/c-nu/nu mice [54]. Both single treatments and the 
combination resulted in reduced osteolysis, and in 
decreased tumour burden in bone and surrounding soft 
tissues. Intriguingly, administration of zoledronic acid 
alone resulted in a 93% reduction of bone-associated soft 
tissue tumour area, but only in a 73% reduction in total 
tumour burden, suggesting a direct eﬀ  ect on tumours 
growing outside the bone microenvironment. Th  ese 
promising data need to be conﬁ  rmed using a treatment 
protocol, to determine whether the combination of 
doxycycline and zoledronic acid can also reduce the 
growth of established breast cancer metastases.
Whether a single administration of a clinically relevant 
dose of zoledronic acid can increase the anti-tumour 
eﬀ  ect of doxorubicin has been investigated using female 
BALB/c-nu/nu mice injected with MDA-MB-231/B02 
human breast cancer cells that speciﬁ  cally metastasise to 
bone [48]. Animals with conﬁ  rmed tumour growth in 
bone were treated with saline, doxorubicin (2 mg/kg, 
days 18 and 25), zoledronic acid (100 μg/kg day 19, 
equivalent to the 4-mg clinical dose), zoledronic acid and 
doxo  rubicin simultaneously, or doxorubicin followed 
24  hours later by zoledronic acid. All the treatment 
schedules that included zoledronic acid caused a 
signiﬁ  cant reduction in osteolytic lesion area compared 
to control or doxorubicin treatment. Th  e most eﬀ  ective 
reduction in intra-osseous tumour burden was found in 
animals that received sequential treatment with 
doxorubicin followed by zoledronic acid. Th  e reduced 
tumour burden in this group was associated with 
increased levels of tumour cell apoptosis and a decrease 
in tumour cell proliferation. In contrast, extra-osseous 
tumour burden was unaﬀ  ected by all of the treatment 
schedules, suggesting that the tumour microenvironment 
as well as diﬀ   erential drug concen  tration in diﬀ  erent 
parts of the tumour may determine the response to 
treatment.
Th  e molecular processes aﬀ   ected by combination 
therapy with doxorubicin and zoledronic acid were 
further elucidated using a model of MDA-MB-436 breast 
cancer cells directly implanted in bone [55]. A 6-week 
course of weekly administration of doxorubicin (2 mg/kg), 
followed 24 hours later by zoledronic acid (100 μg/kg), 
caused substantial inhibition of tumour burden in bone 
compared with administration of the single agents. 
Molecular analysis of the tumours from animals treated 
sequentially with doxorubicin followed by zoledronic 
acid showed reduced numbers of proliferating tumour 
cells, accompanied by decreased levels of expression of 
cyclins E1, B, D1, and D3, as well as cdk2 and cdk4. 
Tumours from the sequential treatment group also 
displayed increased levels of apoptosis, associated with 
increased expression of the pro-apoptotic molecule bax, 
decreased expression of the anti-apoptotic molecule 
bcl-2, and activation of caspases 3, 8, and 9. Doxorubicin 
had no eﬀ  ect on tumour growth, cell cycle, or apoptosis 
in vivo, but did cause increased accumulation of a BP in 
MDA-MB-436 cells in vitro, suggesting that doxorubicin 
may aﬀ   ect subsequent uptake of zoledronic acid. In 
support of this, accumulation of unprenylated Rap1A, a 
surrogate marker of zoledronic acid, was only detected in 
tumours following sequential treatment.
Beneﬁ  ts of adding BPs to combination therapy is not 
limited to zoledronic acid, as demonstrated by a recent 
study using risedronate [56]. Female BALB/c-nu/nu mice 
were inoculated intratibially with MDA-231-B/luc+ cells, 
and treated with risedronate, docetaxel or a combination 
of both. Risedronate, alone or in combination with 
docetaxel, prevented osteolytic bone destruction 
compared to control, whereas administration of 
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was undetectable in six out of seven mice following 
combination treatment, treatment with docetaxel 
prevented tumour growth in two out of seven mice, and 
risedronate treatment had no eﬀ  ect.
Anti-tumour eff  ects of bisphosphonates in breast 
tumours outside bone
A number of diﬀ  erent mechanisms contribute to the ob-
served anti-tumour eﬀ  ects (Figure 3), including reduction 
in tumour macrophage inﬁ   ltration, decreased tumour 
angiogenesis, activation of immune cells, reduction in the 
levels of bone-derived tumour growth factors and eﬀ  ects 
on bone marrow precursors. But could BPs also reduce 
tumour growth outside the skeleton? Many of the 
proposed mechanisms responsible for BPs reducing 
tumour growth in bone would also apply to tumours 
growing at peripheral sites (Figure 2), and this has 
initiated a limited number of studies aimed at deter-
mining whether BPs, alone or in combination with 
chemotherapeutic agents, reduce either the development 
of visceral metastases or directly reduce the growth of 
subcutaneously implanted breast tumours.
Bisphosphonates used as single agents
Th  e eﬀ   ects of zoledronic acid on the development of 
visceral breast cancer metastases have been determined 
using the 4T1 model [57]. While a single dose of 5 μg 
zoledronic acid did not aﬀ  ect tumour burden in visceral 
organs, a repeated dosing regimen signiﬁ  cantly reduced 
the number of metastatic foci in lung and liver. Detailed 
histological analysis revealed that there was no increase 
in the levels of apoptotic 4T1/luc cell death in the lung, 
suggesting that the anti-tumour eﬀ  ect was not mediated 
through increased tumour cell killing. Th  e authors 
concluded that the anti-tumour eﬀ   ects induced by 
zoledronic acid in soft tissues are probably due to 
inhibition of tumour cell invasion and migration. Th  ese 
results were, however, generated through high and 
repeated dosing with zoledronic acid, and the clinical 
relevance of the ﬁ  ndings remains to be established.
Bisphosphonates as part of combination therapy
In order to separate the direct anti-tumour eﬀ  ects of BPs 
from those mediated via bone, Ottewell and colleagues 
[41] investigated whether sequential or combined 
treatment with doxorubicin and zoledronic acid can 
aﬀ   ect subcutaneous breast tumour growth. MDA-G8 
human breast cancer cells (a subclone of MDA-MB-436) 
were injected subcutaneously in the ﬂ  ank of female MF1 
nu/nu mice, and once tumours were palpable, animals 
were treated once per week for 6 weeks with saline, doxo-
rubicin (2 mg/kg), zoledronic acid (100 μg/kg), zoledronic 
acid and doxorubicin together, doxorubicin followed 
24  hours later by zoledronic acid, and vice versa. 
Adminis  tration of the single agents had no signiﬁ  cant 
eﬀ  ect on tumour size compared to saline control, but 
combined administration of the two agents caused 
around 50% reduction in tumour size when compared to 
animals treated with doxorubicin alone. Surprisingly, 
sequential treatment with doxorubicin followed by 
zoledronic acid caused almost complete abolition of 
tumour growth, whereas administration of the reverse 
drug sequence had no eﬀ  ect.
Th  e anti-tumour eﬀ  ect was associated with increased 
levels of cancer cell apoptosis and reduced proliferation 
compared to other treatment groups. Pathway-speciﬁ  c 
gene array analysis showed that at least 30 genes involved 
in cell cycle regulation and apoptosis had been speci  ﬁ  -
cally changed in the tumours following sequential 
Table 3. Overview of studies investigating bisphosphonates as part of combination therapy in breast cancer
Breast cancer model  Bisphosphonate (dose)  Anti-cancer agent (dose)  Eff  ect compared to single agent  Reference
4TC/luc: spontaneous   Zoledronic acid (250 μg/kg  Uracil, tegafl  ur (20 mg/kg/day  Reduced area of bone metastases  [53]
bone metastases  single administration)  for 7 days)
MDA-MB-231:   Zoledronic acid (0.2 μg/mouse  Doxycycline (15 mg/kg/day  Reduced tumour burden in bone and in soft tissue  [54]
intracardiac injection  every 2 days ×9)  for 21 days) 
B02: generates bone   Zoledronic acid (100 μg/kg  Doxorubicin (2 mg/kg  Reduced intra-osseous tumour growth and lytic  [48]
metastases following   single administration)  weekly for 2 weeks)  bone disease 
intravenous injection      No eff  ect on extra-osseous parts of the tumour 
MDA-MB-436:   Zoledronic acid (100 μg/kg  Doxorubicin (2 mg/kg  Maximal reduction of tumour growth when  [41]
subcutaneous tumours  weekly for 6 weeks)  weekly for 6 weeks)  doxorubicin given 24 h prior to zoledronic acid 
      No evidence of tumours in bone
MDA-MB-231luc:   Risedronate (150 μg/kg,   Docetaxel (4 mg/kg,   Reduced tumour burden in bone and reduced  [56]
intratibial implantation  5×/week)  2×/week)  osteolytic lesions
MDA-MB-436:   Zoledronic acid (100 μg/kg  Doxorubicin (2 mg/kg  Reduced tumour burden in bone and reduced  [55]
intratibial implantation  weekly for 6 weeks)  weekly for 6 weeks)  lytic bone disease
MDA-MB-436:   Zoledronic acid (100 μg/kg  Doxorubicin (2 mg/kg  Reduced tumour growth and increased survival  [58]
subcutaneous tumours  weekly for 6 weeks)  weekly for 6 weeks)  Sustained inhibition of tumour growth following 
      6 weeks of treatment
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partly mediated by inhibition of angiogenesis, as both 
combined and sequential treatment (doxorubicin 
followed by zoledronic acid) appeared to cause a major 
reduction in tumour vascularisation. However, the cumu-
lative concen  trations of zoledronic acid used, although 
clinically achievable, still exceed doses used to treat 
advanced breast cancer.
In a follow-up study, the same group reported that a 
6-week course of weekly sequential treatment with 
doxorubicin and zoledronic acid had a sustained anti-
tumour eﬀ  ect, as the tumours did not re-grow in the 
5  months following completion of treatment [58]. 
Detailed molecular analysis of the tumours from the 
diﬀ   er  ent treatment groups showed that sequential 
therapy triggered particular molecular pathways, induc-
ing increased apoptosis and reducing tumour cell 
prolifera  tion. In addition, there was a substantial reduc-
tion in the number of F4/80 positive cells (macrophages) 
inﬁ   ltrating the tumours following sequential adminis-
tration of doxorubicin and zoledronic acid.
Clinical perspective
Th   ere is increasing clinical evidence to support an ‘anti-
tumour eﬀ  ect’ of BPs in breast cancer and indeed other 
malignancies. In addition to the beneﬁ   ts of adjuvant 
zoledronic acid seen in premenopausal oestrogen 
receptor positive (ER+) breast cancer described earlier 
[13], other clinical studies [15,16,59,60] in breast cancer 
have shown intriguing positive results and are reviewed 
elsewhere in this issue. Furthermore, the incidence of 
invasive breast cancer appears to be lower in post-
menopausal women taking oral BPs for breast cancer 
[61-63], survival in multiple myeloma is enhanced with 
zoledronic acid in combination with chemotherapy [64] 
and sequence-dependent anti-tumour eﬀ  ects with doce-
taxel followed by zoledronic acid have been observed in 
prostate cancer [65]. It is becoming increasingly evident 
that BPs are more than just supportive care drugs.
Conclusion
Th  is review has summarised our current understanding 
of the anti-tumour eﬀ  ects of BPs in breast cancer, based 
on data from in vitro and in vivo model systems, as well 
as linking these to recent reports from clinical studies. 
Taken together, there is considerable evidence to show 
that as long as tumour cells are exposed to suﬃ   cient 
doses of BPs, they will be negatively aﬀ  ected by the drugs. 
However, whether this is achieved following clinical 
administration of BPs to a degree that ultimately aﬀ  ects 
tumour growth remains to be determined. Recent data 
suggest that we should not focus exclusively on whether 
BPs target tumour cells directly, but also consider how 
these potent anti-resorptive agents modify cells in the 
bone microenvironment that are essential for tumour 
growth.
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